Maintenance of Patient-Reported Outcomes in Baricitinib-Treated Patients with Moderate-to-Severe Active Rheumatoid Arthritis: Post Hoc Analyses from Two Phase 3 Trials

INTRODUCTION: Baricitinib has been shown to improve patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) who are inadequate responders (IR) to conventional synthetic and biologic disease-modifying antirheumatic drugs (csDMARDs and bDMARDs, respectively). We assessed the abilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sholter, Dalton, Wu, Jianmin, Jia, Bochao, Zhang, Hong, Griffing, Kirstin, Birt, Julie, Reis, Paulo Jorge Simoes, Liu, Huaxiang, Bingham, Clifton O.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964879/
https://www.ncbi.nlm.nih.gov/pubmed/34990002
http://dx.doi.org/10.1007/s40744-021-00415-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8964879/
https://www.ncbi.nlm.nih.gov/pubmed/34990002
http://dx.doi.org/10.1007/s40744-021-00415-8

Ejemplares similares